{"id":"W4397008063","doi":"10.1016/j.esmoop.2024.103019","title":"10P PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy: A biomarker study of the LORELEI trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Institute on the Environment, University of Minnesota; Veracyte; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Eisai; Astellas Pharma; Oncolytics Biotech; Relay Therapeutics; Seagen; MacroGenics; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Sanofi; Breast Cancer Research Foundation; Amgen; Pfizer","keywords":"Biomarker; Neoadjuvant therapy; Oncology; Endocrine system; Mutation; Internal medicine; Medicine; Biology; Cancer; Genetics; Hormone; Breast cancer; Gene","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005164525,0.0001315095,0.0002573768,0.00009125916,0.00006090387,0.00007591844,0.0001254291,0.00003027002,0.0001310753],"category_scores_gemma":[0.0001955062,0.00007739292,0.00003147129,0.0002544536,0.00004352509,0.00008545132,0.0002381671,0.00009256009,0.00001118037],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001479768,"about_ca_system_score_gemma":0.0002661734,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002087754,"about_ca_topic_score_gemma":0.00027094,"domain_scores_codex":[0.9988858,0.0002200727,0.0002359017,0.0003082455,0.0002163284,0.0001337159],"domain_scores_gemma":[0.9992386,0.0002575717,0.00004210912,0.0003467134,0.00003215965,0.00008280974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5060276,0.002915464,0.01354734,0.0001714323,0.002194872,0.002501318,0.03987744,0.000008988931,0.0147847,0.0001431354,0.01603644,0.4017912],"study_design_scores_gemma":[0.2931842,0.01606357,0.6169385,0.0006774809,0.0006237488,0.0006346383,0.004282331,0.0006706218,0.007533725,0.0001790794,0.05884064,0.0003714354],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924355,0.0005413495,0.000002753463,0.002343256,0.0001994755,0.004088737,0.00001898439,0.00002038575,0.000349516],"genre_scores_gemma":[0.9979426,0.00005458651,0.00009066742,0.0001652453,0.00004952928,0.000169706,0.000008997461,0.00002161677,0.001497057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6033912,"threshold_uncertainty_score":0.3156074,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04233489190041899,"score_gpt":0.3595692542732487,"score_spread":0.3172343623728297,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}